There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

After Wegovy and Ozempic by pharmaceutical company Novo Nordisk, Netherlands residents will soon also have access to another ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...

In a report released today, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

Eli Lilly & Co. closed $85.37 below its 52-week high ($972.53), which the company reached on August 22nd.

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...